Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.

Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, André T, Mareel M, Mester J, Gespach C.

Cancer Res. 2002 Sep 1;62(17):4879-83.

3.

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.

Croom KF, Perry CM.

Drugs. 2003;63(5):513-22; discussion 523-4. Review.

PMID:
12600228
4.

[Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].

Molnár L, Losonczy H.

Orv Hetil. 2002 Oct 20;143(42):2379-84. Review. Hungarian.

PMID:
12440260
5.

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW.

Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98. Review.

PMID:
12191602
6.

The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer.

Roussidis AE, Theocharis AD, Tzanakakis GN, Karamanos NK.

Curr Med Chem. 2007;14(7):735-43. Review.

PMID:
17346159
7.

Pharmacology of imatinib (STI571).

Buchdunger E, O'Reilly T, Wood J.

Eur J Cancer. 2002 Sep;38 Suppl 5:S28-36. Review.

PMID:
12528770
9.

Molecularly targeted therapy for gastrointestinal cancer.

Wiedmann MW, Caca K.

Curr Cancer Drug Targets. 2005 May;5(3):171-93. Review.

PMID:
15892618
10.

Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.

Deininger MW.

J Cancer Res Clin Oncol. 2004 Feb;130(2):59-72. Review.

PMID:
14605878
11.

[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology].

Hochhaus A, Lahaye T, Kreil S, Berger U, Metzgeroth G, Hehlmann R.

Onkologie. 2001 Sep;24 Suppl 5:65-71. Review. German.

PMID:
11600816
12.

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.

Capdeville R, Buchdunger E, Zimmermann J, Matter A.

Nat Rev Drug Discov. 2002 Jul;1(7):493-502. Review.

PMID:
12120256
13.

Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.

Roskoski R Jr.

Biochem Biophys Res Commun. 2005 Dec 23;338(3):1307-15. Review.

PMID:
16226710
14.

Tyrosine kinase inhibitors: from rational design to clinical trials.

Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J.

Med Res Rev. 2001 Nov;21(6):499-512. Review.

PMID:
11607931
15.

[Tyrosine kinases. New target of anticancer therapy].

Majsterek I, Pytel D, Błasiak J.

Postepy Biochem. 2005;51(3):251-60. Review. Polish.

PMID:
16381169
16.

Stem cell factor: laboratory and clinical aspects.

Smith MA, Court EL, Smith JG.

Blood Rev. 2001 Dec;15(4):191-7. Review.

PMID:
11792120
17.

In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.

Decaudin D, de Cremoux P, Sastre X, Judde JG, Nemati F, Tran-Perennou C, Fréneaux P, Livartowski A, Pouillart P, Poupon MF.

Int J Cancer. 2005 Feb 20;113(5):849-56. Review.

18.

Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors.

Pittoni P, Piconese S, Tripodo C, Colombo MP.

Oncogene. 2011 Feb 17;30(7):757-69. doi: 10.1038/onc.2010.494. Review.

PMID:
21057534
19.
20.

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

Heinrich MC, Blanke CD, Druker BJ, Corless CL.

J Clin Oncol. 2002 Mar 15;20(6):1692-703. Review.

PMID:
11896121
Items per page

Supplemental Content

Support Center